|
|
Article: Antares Pharma, Inc. and Ferring Pharmaceuticals Announce Extension of Their Business Relationship for Use of Needle-Free Devices for Delivery of Human Growth Hormone.
- Article from:
- PR Newswire
- Article date:
- February 12, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antares Pharma, Inc. and Ferring Pharmaceuticals announced today that the two companies have initiated a longer-term business relationship for the continuing development and supply of needle-free delivery devices to the human growth hormone market. Ferring currently markets the ZOMAJET(R) 2 VISION, Ferring's trade name for Antares Pharma's Medi-Jector VISION(R) device, for use with Ferring's growth hormone product, ZOMACTON(R). As part of the extended agreement, Ferring will access next-generation devices from Antares Pharma to further support the development of current and future markets for human growth hormone. Under the terms of the agreement, Antares Pharma will ...
Related newspaper, magazine, and journal articles:
|
|
Article: Antares Pharma Reacquires U.S. Growth Hormone ...
PR Newswire;
February 7, 2003 ;
700+ words
... ... exclusive license to Antares Pharma's needle-free ... and President of Antares Pharma, said, "The U ... hormone partner, Ferring Pharmaceuticals, in which they ... conventional needles." Antares Pharma's needle-free ...
|
|